Press Releases | Advaxis, Inc. Investor Center

Press Releases

Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018
Mar 26, 2018
Advaxis to Present at Upcoming March Conferences
Mar 13, 2018
Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)
Mar 12, 2018
Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018
Mar 9, 2018
Advaxis Prices $20.0 Million Public Offering of Common Stock
Feb 22, 2018
Advaxis Announces Proposed Public Offering of Common Stock
Feb 21, 2018
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union
Feb 13, 2018
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer
Feb 12, 2018
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies
Jan 29, 2018
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology
Jan 25, 2018

Business Wire InvestorHQ^sm